Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
Maaike E. Ressing(Utrecht University), W. Martin Kast(University of Southern California), Carla Oseroff(La Jolla Institute for Immunology), J Ruppert(Cytel (United States)), Cornelis J.M. Melief(ISA Pharmaceuticals (Netherlands)), H M Grey, Peggy Wentworth(Leiden University), Alessandro Sette(La Jolla Institute for Immunology), M. Hartman(Leiden University), Remco M.P. Brandt(Leiden University)
Cited by 386
Related Papers
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
|Cell|2020|4k
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
|European Journal of Immunology|1993|840